Holzer & Holzer, LLC is investigating whether certain statements made by Esperion Therapeutics, Inc. (“Esperion” or the “Company”) (NASDAQ: ESPR) between August 18, 2015 and September 28, 2015 regarding, among other things, the Company’s efforts to obtain regulatory approval of its developmental cholesterol drug, ETC-1002, complied with federal securities laws.

If you purchased Esperion common stock between August 18, 2015 and September 28, 2015 and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. via email at cholzer@holzerlaw.com or via toll-free telephone at (888) 508-6832, to discuss your legal rights.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.